LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships14.1.2025 14:35:05 EET | LTS Lohmann Therapie-Systeme AG | Press release
Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies. The Patch Forward Prize, part of the Project NextGen initiative led by BARDA, aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health. Each of the prizes announced today represents an award of US$ 2 million, that will be shared between LTS and its partners. The awarded projects bring together LTS’s proprietary dissolvable Microneedle Array Patch (MAP) technology with mRNA vaccines from two partners, BioNet, a biotech man